Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Real-World, Observational Study Investigating Lenalidomide Maintenance (R-MT) Treatment after Lenalidomide, Bortezomib, and Dexamethasone (RVD) Induction and Stem Cell Transplant (SCT) in High-Risk (HR) Patients with Newly Diagnosed Multiple Myeloma (NDMM)

Trial Profile

A Real-World, Observational Study Investigating Lenalidomide Maintenance (R-MT) Treatment after Lenalidomide, Bortezomib, and Dexamethasone (RVD) Induction and Stem Cell Transplant (SCT) in High-Risk (HR) Patients with Newly Diagnosed Multiple Myeloma (NDMM)

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 24 Jun 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lenalidomide (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Jun 2018 New trial record
    • 17 Jun 2018 Results (n=85) presented at the 23rd Congress of the European Haematology Association.
    • 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top